Third dose of COVID-19 vaccine, CVnCoV, increased neutralizing activity against SARS-CoV-2 wild-type and Delta variant
Preprint
Abstract
A third dose of CVnCoV, a former candidate mRNA vaccine against SARS-CoV-2, was previously shown to boost neutralizing antibody responses against SARS-CoV-2 wild-type in adults aged 18-60 and >60 years in a phase 2a clinical study. Here we report neutralizing antibody responses to wild-type and a variant of concern, Delta, after a third dose on day (D) 57 and D180. Neutralization activity was assessed using a microneutralization assay. Comparable levels of neutralizing antibodies against wild-type and Delta were induced. These were higher than those observed after the first two doses, irrespective of age or pre-SARS-CoV-2-exposure status, indicating that the first two doses induced immune memory. Four weeks after the third dose on D180, neutralizing titers for wild-type and Delta were two-fold higher in younger participants than in older participants; seroconversion rates were 100% for wild-type and Delta in the younger group and for Delta in the older group. A third CVnCoV dose induced similar levels of neutralizing responses against wild-type virus and the Delta variant in both naïve and pre-exposed participants, aligning with current knowledge from licensed COVID-19 vaccines that a third dose is beneficial against SARS-CoV-2 variants.Keywords
All Related Versions
- Published version: Vaccines, 10 (4), 508.
This publication has 10 references indexed in Scilit:
- The Impact of Age Difference on the Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-AnalysisFrontiers in Immunology, 2021
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialThe Lancet, 2021
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccineNature, 2021
- Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysisThe Lancet Microbe, 2021
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3New England Journal of Medicine, 2021
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysisNature Medicine, 2021
- Impact of the Delta variant on vaccine efficacy and response strategiesExpert Review of Vaccines, 2021
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationNature, 2021
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasmaNature Medicine, 2021
- SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular responseEmerging Microbes & Infections, 2021